Learn languages naturally with fresh, real content!
Popular Topics
Explore By Region
1. Genentech's subcutaneous Ocrevus shows near-complete suppression of relapses (97%) and brain lesions (97.2%) in MS patients after one year in a Phase III study.
17 months ago
4 Articles